Pharmacokinetic characteristics and hepatic distribution of IH-901, a novel intestinal metabolite of ginseng saponin, in rats

Planta Medica

Volumn 72, Issue 3, 2006, Pages 204-210

  Lee, Pung Sok ^a   Song, Tae Won ^a   Sung, Jong Hwan ^b   Moon, Dong Cheul ^a   Song, Sukgil ^a   Chung, Youn Bok ^a  

^a Chungbuk National University   (South Korea)

^b IL HWA Co Ltd   (South Korea)

Author keywords

Araliaceae; Bioavailability; Ginseng saponin metabolite (IH 901); Hepatic distribution; Panax ginseng; Pharmacokinetics

Indexed keywords

20 O (BETA DEXTRO GLUCOPYRANOSYL) 20(S) PROTOPANAXADIOL; GINSENG SAPONIN; PROTOPANAXADIOL 20 GLUCOSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; DRUG URINE LEVEL; INTESTINE FLORA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; NONHUMAN; RAT; STEADY STATE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; INFUSIONS, INTRAVENOUS; LIVER; MALE; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SAPONINS; TISSUE DISTRIBUTION;

ANIMALIA; ARALIACEAE; PANAX GINSENG;

EID: 33645012866     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916201     Document Type: Article

References (19)

1. Kikuchi Y, Sasa H, Kita T, Hirata J, Tode T, Nagata I. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 1991; 2: 63-7
2. Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E, Nagata I. Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice. J Cancer Res Chin Oncol 1993; 120: 24-6
3. Lee YN, Lee HY, Chung HY, Kim SI, Lee SK, Park BC et al. In vitro induction of differentiation by ginsenosides in F9 teratocarcinoma cells. Eur J Cancer 1996; 32A: 1420-8
4. Park JA, Lee KY, Oh YJ, Kim KW, Lee SK. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett 1997; 121: 73-81
5. Shinkai K, Akedo H, Mukai M, Imamura F, Isoai A, Kobayashi M et al. Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Jpn J Cancer Res 1996; 87: 357-62
6. Iishi H, Tatsuta M, Baba M, Uehara H, Nakaizumi A, Shinkai K et al. Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin Exp Metastasis 1997; 15: 603-11
7. Hasegawa H, Sung JH, Matsumiya S, Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 1996; 62: 453-7
8. Hasegawa H, Sung JH, Huh JD. Ginseng intestinal bacterial metabolite IH901 as a new antimetastatic agent. Arch Pharm Res 1997; 20: 539-44
9. Hasegawa H, Matsumiya S, Uchiyama M, Kurokawa T, Inouye Y, Kasai R et al. Inhibitory effect of some triterpenoid saponins on glucose transport in tumor cells and its application to in vitro cytotoxic and antiviral activities. Planta Med 1995; 60: 240-3
10. Hasegawa H, Sung JH, Matsumiya S, Uchiyama M, Inouye Y, Kasai R et al. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med 1995; 61: 409-13
11. Lee BH, Lee SJ, Hur JH, Lee S, Sung JH, Huh JD, Moon CK. In vitro anti-genotoxic activity of novel ginseng saponin metabolites formed by intestinal bacteria. Planta Med 1998; 64: 500-3
12. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003; 84: 187-92
13. Wang H, Zou H, Kong L, Zhang Y, Pang H, Su C et al. Determination of ginsenoside Rg3 in plasma by solid-phase extraction and high-performance liquid chromatography for pharmacokinetic study. J Chromatogr B 1999; 731: 403-9
14. Cai Z, Qian T, Wong RNS, Jiang ZH. Liquid chromatography lectrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3. Anal Chim Acta 2003; 492: 283-93
15. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 1998; 50: 1155-60
16. Akao T, Kanaoka M, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration: measurement of compound K by enzyme immunoassay. Biol Pharm Bull 1998; 21: 245-9
17. Yamaoka K, Tanigawara Y, Nakagawa Y, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 1981;4: 879-85
18. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993; 264:27: G36-G44
19. Hasegawa H, Lee KS, Nagaoka T, Tezuka Y, Uchiyama M, Kadota S et al. Pharmacokinetics of ginsenoside deglycosylated by intestinal bacteria and its transformation to biologically active fatty acid esters. Biol Pharm Bull 2000; 23: 298-304